Gregory Glenn
Keine laufenden Positionen mehr
Vermögen: 87 660 $ am 31.03.2024
Profil
Gregory M. Glenn gründete Intercell USA, Inc. Dr. Glenn ist President-Research & Development bei Novavax, Inc. Zuvor war er Chief Scientific Officer bei der Intercell AG, Chief Scientific Officer & Senior Vice President bei Intercell USA, Inc. sowie Forschungswissenschaftler am Walter Reed Army Institute of Research und Associate-International Health an der Johns Hopkins Bloomberg School of Public Health. Dr. Glenn erhielt einen Undergraduate-Abschluss vom Whitman College und einen Doktortitel von der Oral Roberts University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NOVAVAX, INC.
0,01% | 18.04.2023 | 18 339 ( 0,01% ) | 87 660 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Gregory Glenn
| Unternehmen | Position | Ende |
|---|---|---|
| NOVAVAX, INC. | Chief Tech/Sci/R&D Officer | 31.03.2023 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 01.01.2010 |
| IOMAI CORPORATION | Founder | 01.01.2008 |
| Walter Reed Army Institute of Research | Corporate Officer/Principal | - |
| Johns Hopkins Bloomberg School of Public Health | Corporate Officer/Principal | - |
Ausbildung von Gregory Glenn
| Oral Roberts University | Doctorate Degree |
| Whitman College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NOVAVAX, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
 Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
| Walter Reed Army Institute of Research |
